Evidence map›Paper›PMID 20957163›Full record

ArticleInternational journal of nanomedicine2010

Mechanisms of cell death in canine parvovirus-infected cells provide intuitive insights to developing nanotools for medicine.

Jonna Nykky, Jenni E Tuusa, Sanna Kirjavainen, Matti Vuento, Leona Gilbert

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. The effects of leukocyteBMC veterinary research · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Nuclear entry and egress of parvoviruses.Molecular microbiology · 2022
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Viral genes as oncolytic agents for cancer therapy.Cellular and molecular life sciences : CMLS · 2015
    Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jonna NykkyNanoscience Center and Department of Biological and Environmental Science, University of Jyväskylä, Finland.
Jenni E Tuusa
Sanna Kirjavainen
Matti Vuento
Leona Gilbert

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viruses have great potential as nanotools in medicine for gene transfer, targeted gene delivery, and oncolytic cancer virotherapy. Here we have studied cell death mechanisms of canine parvovirus (CPV) to increase the knowledge on the CPV life cycle in order to facilitate the development of better parvovirus vectors. Morphological studies of CPV-infected Norden laboratory feline kidney (NLFK) cells and canine fibroma cells (A72) displayed characteristic apoptotic events. Apoptosis was further confirmed by activation of caspases and cellular DNA damage. However, results from annexin V-propidium iodide (PI) labeling and membrane polarization assays indicated disruption of the plasma membrane uncommon to apoptosis. These results provide evidence that secondary necrosis followed apoptosis. In addition, two human cancer cell lines were found to be infected by CPV. This necrotic event over apoptotic cell death and infection in human cells provide insightful information when developing CPV as a nanotool for cancer treatments.

Indexed as

Cell DeathAnimalsApoptosisCaspasesCatsCell CycleCell LineDNA DamageDNA FragmentationDogsFlow CytometryGene ExpressionHeLa CellsHumansMembrane Potential, MitochondrialMicroscopy, Electron, TransmissionCaspasesNS1 protein, parvovirusViral Nonstructural Proteinsapoptosiscanine parvovirusnanoparticlenecrosisvirotherapy

Identifiers

PMID20957163
PMCPMC2950399

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.